Articles On Memphasys (ASX:MEM)

Summary The ASX 200 opened higher by 0.10% on Tuesday after the US stocks closed on a strong note overnight. The domestic benchmark rose to a two-week high, as a more than 3% jump in oil prices boosted energy stocks. On Monday, the do...

Medtech company Oneview Health (ASX:ONE) led 25 stocks that chalked up a 14-day RSI above 70 this week, up slightly from 22 in the week prior. Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: S_L ,Shutterstock Summary Memphasys Limited revealed that the validation process of its Felix Device had been delayed. The Company identified a flaw in the device, which is likely to reduce the Felix system’s effectiveness. M...

Sperm sorter Memphasys (ASX:MEM) is down 40 per cent after a major setback. The company’s Felix device can extract viable ... Read More The post Memphasys shares tumble 35pc after engineering flaw identified appeared first on Stockhead.

Ellume, a small Brisbane-based private biotech company, is in the news today. And for good reason – Ellume has just received an endorsement from the all-powerful United States Food and Drug Administration (FDA). According to reporting in T...

The companies have been recognised for design and engineering excellence at the Good Design Awards.

A quick wrap of the ASX’s key winners and losers on Monday, July 27. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 722 stocks rose, 625 declined and 755...

ShareCafeWhat Have Been The Best “Hidden Gems” Webinar Performers? Over the past three months, ShareCafe has provided investors with the opportunity to connect and engage directly with many listed ASX companies. Our webinar series has provi...

A quick wrap of the ASX’s key winners and losers on Friday, July 10. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 510 stocks rose, 793 decl...

ShareCafeMemphasys Ltd – ShareCafe Hidden Gems Webinar Presentation   Memphasys Ltd CEO and Executive Chairman Alison Coutts presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Memphasys is an Australian publicly-listed bio-sep...

ShareCafeHidden Gems Webinar Recap – SPT, KZA, MEM, ANP   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the most recent edition with presentations from Splitit Payments Ltd (ASX:SPT), Kaz...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 59 were in positive territory over the last fortnight, 22 were flat and 58 saw t...

A quick wrap of the key winners and losers on Friday, May 1. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Code Company Price % Change Volume...

The announcement lands just before markets open, ‘the TGA has approved our device’; the buy orders begin to pile up and the pre-open share price begins to surge. But while a nod from Australia’s drug and device regulator, the Therapeutic Go...

ShareCafeMemphasys – The Business Of IVF Treatments Memphasys – The Business Of IVF TreatmentsCompany News

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Alison Coutts, executive chair of Memp...

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

Did the doc say to take one pill twice daily, or two tablets once daily? When it comes to correct medication, it’s easy to get it wrong. Because of misreading instructions, forgetfulness, laziness or nasty side effects Australians aren’t es...

Did you know that a hard-working stallion ejaculates 100 times more sperm than the average bloke? Given a virile, but weary, thoroughbred can service hundreds of mares in a breeding season, that’s just as well. But even the most virile of t...

This year has been a positive one for ASX small caps. According to Bloomberg, the average small cap has gained just under 5 per cent and some of the major sectors have seen double digit percentage gains. One example is the health sector whi...

Australian Health Care is a dynamic sector with a potential to generate significant profits in the least amount of time, something, what investors eye for, while pouring cash in Stocks. In this article we will be digging into four Health Ca...

On Stockhead today: the three biggest opportunities for digital transformation in pharma, why it’s time to get excited about cobalt again, the top 10 stocks that doubled (and even tripled) in 24 hours and the stocks investors are shorting r...